European Journal of Cancer
Volume 41, Issue 18 , Pages 2873-2881 , December 2005

Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells

  • N. Binz

      Affiliations

    • Department of Oncology, University Children’s Hospital of Zurich, Steinwiesstrasse 75, Hospital, 8032 Zurich, Switzerland
    • These authors contributed equally to this work.
    • ,
  • T. Shalaby

      Affiliations

    • Department of Oncology, University Children’s Hospital of Zurich, Steinwiesstrasse 75, Hospital, 8032 Zurich, Switzerland
    • These authors contributed equally to this work.
    • ,
  • P. Rivera

      Affiliations

    • Department of Oncology, University Children’s Hospital of Zurich, Steinwiesstrasse 75, Hospital, 8032 Zurich, Switzerland
    • ,
  • K. Shin-ya

      Affiliations

    • Institute of Molecular and Cellular Biosciences, The University of Tokyo, Japan
    • ,
  • M.A. Grotzer

      Affiliations

    • Department of Oncology, University Children’s Hospital of Zurich, Steinwiesstrasse 75, Hospital, 8032 Zurich, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 1 266 71 11; fax: +41 1 266 71 71.

Received 8 February 2005 ,Revised 5 August 2005 ,Accepted 16 August 2005.

References 

  1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–216
  2. Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10(1 Pt 1):4–12
  3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70
  4. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33(5):787–791
  5. Bryan TM, Cech TR. Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol. 1999;11(3):318–324
  6. Bryan TM, Englezou A, Gupta J, et al. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 1995;14(17):4240–4248
  7. Neumann AA, Reddel RR. Telomere maintenance and cancer – look, no telomerase. Nat Rev Cancer. 2002;2(11):879–884
  8. Henson JD, Neumann AA, Yeager TR, et al. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21(4):598–610
  9. Blackburn EH. Structure and function of telomeres. Nature. 1991;350(6319):569–573
  10. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science. 1995;269(5228):1236–1241
  11. Bosoy D, Peng Y, Mian IS, et al. Conserved N-terminal motifs of telomerase reverse transcriptase required for ribonucleoprotein assembly in vivo. J Biol Chem. 2003;278(6):3882–3890
  12. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011–2015
  13. Mu J, Wei LX. Telomere and telomerase in oncology. Cell Res. 2002;12(1):1–7
  14. Maitra A, Yashima K, Rathi A, et al. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors. Cancer. 1999;85(3):741–749
  15. Reynolds CP, Zuo JJ, Kim NW, et al. Telomerase expression in primary neuroblastomas. Eur J Cancer. 1997;33(12):1929–1931
  16. Krams M, Hero B, Berthold F, et al. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am J Pathol. 2003;162(3):1019–1026
  17. Poremba C, Willenbring H, Hero B, et al. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann Oncol. 1999;10(6):715–721
  18. Nozaki C, Horibe K, Iwata H, et al. Prognostic impact of telomerase activity in patients with neuroblastoma. Int J Oncol. 2000;17(2):341–345
  19. Poremba C, Scheel C, Hero B, et al. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol. 2000;18(13):2582–2592
  20. Choi LM, Kim NW, Zuo JJ, et al. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Med Pediatr Oncol. 2000;35(6):647–650
  21. Zahler AM, Williamson JR, Cech TR, et al. Inhibition of telomerase by G-quartet DNA structures. Nature. 1991;350(6320):718–720
  22. Neidle S, Parkinson G. Telomere maintenance as a target for anticancer drug discovery. Nat Rev Drug Discov. 2002;1(5):383–393
  23. Mergny JL, Riou JF, Mailliet P, et al. Natural and pharmacological regulation of telomerase. Nucleic Acids Res. 2002;30(4):839–865
  24. Shin-ya K, Wierzba K, Matsuo K, et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc. 2001;123(6):1262–1263
  25. Rosu F, Gabelica V, Shin-ya K, et al. Telomestatin-induced stabilization of the human telomeric DNA quadruplex monitored by electrospray mass spectrometry. Chem Commun (Camb). 2003;21:2702–2703
  26. Gomez D, Paterski R, Lemarteleur T, et al. Interaction of telomestatin with the telomeric single-strand overhang. J Biol Chem. 2004;23:23
  27. Kim MY, Vankayalapati H, Shin-Ya K, et al. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc. 2002;124(10):2098–2099
  28. Kim MY, Gleason-Guzman M, Izbicka E, et al. The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res. 2003;63(12):3247–3256
  29. Gomez D, Aouali N, Renaud A, et al. Resistance to senescence induction and telomere shortening by a G-quadruplex ligand inhibitor of telomerase. Cancer Res. 2003;63(19):6149–6153
  30. Tauchi T, Shin-Ya K, Sashida G, et al. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene. 2003;22(34):5338–5347
  31. Shammas MA, Reis RJ, Li C, et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res. 2004;10(2):770–776
  32. Didiano D, Shalaby T, Lang D, et al. Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-oncol. 2004;6(1):1–8
  33. Giulietti A, Overbergh L, Valckx D, et al. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001;25(4):386–401
  34. Grotzer MA, Eggert A, Zuzak TJ, et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene. 2000;19:4604–4610
  35. Oh BK, Kim YJ, Park C, et al. Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol. 2005;166(1):73–80
  36. Iwano T, Tachibana M, Reth M, et al. Importance of TRF1 for functional telomere structure. J Biol Chem. 2004;279(2):1442–1448
  37. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2(4):257–265
  38. Risitano A, Fox KR. The stability of intramolecular DNA quadruplexes with extended loops forming inter- and intra-loop duplexes. Org Biomol Chem. 2003;1(11):1852–1855
  39. White LK, Wright WE, Shay JW. Telomerase inhibitors. Trends Biotechnol. 2001;19(3):114–120
  40. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 2002;295(5564):2446–2449
  41. El-Daly H, Kull M, Zimmermann S, et al. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood. 2004;
  42. Zhu XD, Niedernhofer L, Kuster B, et al. ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol Cell. 2003;12(6):1489–1498
  43. Smogorzewska A, Karlseder J, Holtgreve-Grez H, et al. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol. 2002;12(19):1635–1644
  44. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol. 2003;13(17):1549–1556
  45. Lemarteleur T, Gomez D, Paterski R, et al. Stabilization of the c-myc gene promoter quadruplex by specific ligands’ inhibitors of telomerase. Biochem Biophys Res Commun. 2004;323(3):802–808
  46. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell. 2003;114(2):241–253
  47. Rezler EM, Bearss DJ, Hurley LH. Telomeres and telomerases as drug targets. Curr Opin Pharmacol. 2002;2(4):415–423
  48. Riou JF, Gomez D, Lemarteleur T, et al. G-quadruplex DNA: myth or reality?. Bull Cancer. 2003;90(4):305–313
  49. Darnell JC, Jensen KB, Jin P, et al. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell. 2001;107(4):489–499

PII: S0959-8049(05)00788-4

doi: 10.1016/j.ejca.2005.08.025

European Journal of Cancer
Volume 41, Issue 18 , Pages 2873-2881 , December 2005

Article Tools

* Image Usage & Resolution